Ranibizumab Improved Visual Outcomes in DME
Patients with DME achieved better long-term visual
outcomes when treated with ranibizumab (Lucentis,
Genentech) and focal/grid laser combination therapy
than with ranibizumab or laser alone, according to the
results of the phase 2 READ-2 study published in
Ophthalmology.1 Combining the two treatments also
reduced the ...